Bortezomib Injection IP 2mg
BORTELIEVA 2 MG (Bortezomib Injection IP 2 mg) is a prescription anticancer medicine containing Bortezomib 2 mg, a targeted therapy primarily used in the treatment of Multiple Myeloma and Mantle Cell Lymphoma (MCL). It belongs to a class of medicines known as proteasome inhibitors, which help destroy cancer cells by interfering with essential cellular processes required for their growth and survival.
Multiple Myeloma is a cancer of plasma cells, a type of white blood cell responsible for producing antibodies. When plasma cells become abnormal and multiply uncontrollably, they can damage bones, kidneys, and the immune system. Mantle Cell Lymphoma is a rare and aggressive form of non-Hodgkin lymphoma that affects B-lymphocytes within the lymphatic system. BORTELIEVA 2 MG is specifically designed to target these cancer cells and help slow disease progression.
Bortezomib works by blocking the activity of proteasomes, specialized structures inside cells that remove damaged or unnecessary proteins. Cancer cells rely heavily on proteasomes to maintain their rapid growth. By inhibiting proteasome activity, Bortezomib causes protein accumulation within cancer cells, leading to cellular stress, disruption of cancer cell function, and eventual cell death.
BORTELIEVA 2 MG is commonly prescribed for:
Multiple Myeloma
Newly Diagnosed Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
Mantle Cell Lymphoma (MCL)
Recurrent Blood Cancers
Combination Chemotherapy and Targeted Therapy Programs
Advanced Hematological Malignancies
Specialized Oncology and Hematology Care
The medicine may be administered alone or in combination with other anticancer agents depending on the patient's condition, treatment history, and clinical requirements.
Manufactured under stringent pharmaceutical quality standards, BORTELIEVA 2 MG is designed to provide consistent quality, safety, and therapeutic effectiveness. The injection should only be administered by qualified healthcare professionals experienced in oncology and hematology treatment.
Patients receiving Bortezomib therapy often require routine blood tests, liver function monitoring, kidney assessments, neurological evaluations, and regular clinical follow-up to ensure safe and effective treatment.
Due to its established effectiveness in managing blood cancers, BORTELIEVA 2 MG remains an important component of modern cancer treatment protocols worldwide.
View Details
Cytarabine Injection BP 100mg
CYTLIEVA 100 MG (Cytarabine Injection BP 100 mg) is a prescription anticancer medicine containing Cytarabine 100 mg, a chemotherapy drug widely used in the treatment of various blood cancers, particularly Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), and certain types of lymphoma. Cytarabine belongs to a class of medicines known as antimetabolites, which work by interfering with DNA synthesis in rapidly dividing cancer cells, helping to stop their growth and multiplication.
Blood cancers develop when abnormal cells in the bone marrow grow uncontrollably and interfere with the production of healthy blood cells. These cancerous cells can spread throughout the bloodstream and affect multiple organs. CYTLIEVA 100 MG is designed to target these rapidly dividing malignant cells and support effective cancer management through proven chemotherapy protocols.
Cytarabine has been a cornerstone of leukemia treatment for several decades and remains one of the most commonly used chemotherapy agents in hematology and oncology. It is frequently administered as part of induction, consolidation, and maintenance therapy regimens to achieve remission and reduce the risk of disease recurrence.
CYTLIEVA 100 MG is commonly prescribed for:
Acute Myeloid Leukemia (AML)
Acute Lymphoblastic Leukemia (ALL)
Chronic Myelogenous Leukemia (CML) Blast Crisis
Non-Hodgkin Lymphoma
Meningeal Leukemia
Hematological Malignancies
Combination Chemotherapy Protocols
Advanced Oncology and Hematology Treatment Programs
The medicine may be administered alone or in combination with other anticancer agents depending on the patient's diagnosis, disease stage, treatment goals, and overall health condition.
Manufactured under stringent pharmaceutical quality standards, CYTLIEVA 100 MG is designed to provide consistent therapeutic effectiveness, safety, and reliability. The injection should only be administered by qualified healthcare professionals experienced in oncology and hematology treatment.
Patients receiving Cytarabine therapy often require routine blood tests, liver and kidney function assessments, bone marrow evaluations, and ongoing clinical monitoring to ensure safe and effective treatment.
Due to its established efficacy in treating leukemia and other blood cancers, CYTLIEVA 100 MG remains an essential medicine in modern cancer care worldwide.
View Details
Bendamustine Hydrochloride for Injection 100mg
BENDALIEVA 100 MG (Bendamustine Hydrochloride for Injection 100 mg) is a prescription anticancer medicine used in the treatment of various hematological malignancies, including Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin Lymphoma (NHL), and certain other blood-related cancers. It contains Bendamustine Hydrochloride 100 mg, a potent chemotherapy agent that combines the properties of an alkylating agent and an antimetabolite, helping to destroy cancer cells and slow disease progression.
Blood cancers develop when abnormal white blood cells grow uncontrollably and interfere with the body's ability to produce healthy blood cells. These abnormal cells can accumulate in the bone marrow, lymph nodes, spleen, and bloodstream, affecting normal immune function and overall health. BENDALIEVA 100 MG is specifically designed to target these rapidly dividing cancer cells and help control their growth.
Bendamustine works by damaging the DNA of cancer cells, preventing them from replicating and surviving. Unlike some traditional chemotherapy medicines, Bendamustine has a unique chemical structure that enables it to attack cancer cells through multiple mechanisms. This makes it an important treatment option for patients with certain blood cancers, including those who may not respond adequately to other therapies.
BENDALIEVA 100 MG is commonly prescribed for:
Chronic Lymphocytic Leukemia (CLL)
Non-Hodgkin Lymphoma (NHL)
Indolent B-Cell Lymphoma
Relapsed or Refractory Lymphoma
Hematological Malignancies
Combination Chemotherapy Protocols
Advanced Blood Cancer Treatment Programs
Specialized Oncology and Hematology Care
The medicine may be used alone or in combination with other anticancer therapies depending on the patient's diagnosis, treatment history, and clinical condition.
Manufactured under stringent pharmaceutical quality standards, BENDALIEVA 100 MG is designed to provide consistent therapeutic effectiveness, safety, and reliability. The injection should only be administered by qualified healthcare professionals experienced in oncology and hematology treatment.
Patients receiving Bendamustine therapy often require regular blood tests, liver and kidney function monitoring, infection screening, and routine clinical evaluations to ensure safe and effective treatment.
Due to its established effectiveness in managing blood cancers, BENDALIEVA 100 MG remains an important component of modern cancer treatment protocols worldwide.
View Details
Carfilzomib for Injection 60mg
CARFLIEVA 60 MG (Carfilzomib for Injection 60 mg) is a prescription anticancer medicine used in the treatment of Multiple Myeloma, a type of blood cancer that affects plasma cells in the bone marrow. It contains Carfilzomib 60 mg, a highly effective proteasome inhibitor that helps slow the growth and spread of cancer cells by disrupting essential cellular functions required for their survival.
Multiple Myeloma develops when abnormal plasma cells multiply uncontrollably in the bone marrow, interfering with the production of healthy blood cells and causing complications such as bone damage, anemia, kidney dysfunction, and weakened immunity. CARFLIEVA 60 MG is specifically designed to target these cancerous plasma cells and support long-term disease management.
Carfilzomib works by selectively inhibiting proteasomes, which are protein complexes responsible for breaking down damaged or unnecessary proteins inside cells. Cancer cells rely heavily on proteasome activity to maintain rapid growth and survival. By blocking this process, Carfilzomib causes toxic protein accumulation within cancer cells, leading to cellular stress and ultimately triggering cancer cell death.
CARFLIEVA 60 MG is commonly prescribed for:
Multiple Myeloma
Relapsed Multiple Myeloma
Refractory Multiple Myeloma
Advanced Plasma Cell Disorders
Combination Targeted Therapy Programs
Hematological Malignancies
Oncology and Hematology Treatment Protocols
Long-Term Multiple Myeloma Management
The medicine is often used in combination with other anticancer agents such as dexamethasone, lenalidomide, or other therapies to improve treatment outcomes and enhance disease control.
Manufactured under stringent pharmaceutical quality standards, CARFLIEVA 60 MG is designed to provide consistent quality, safety, and therapeutic effectiveness. The injection should only be administered by qualified healthcare professionals experienced in oncology and hematology care.
Patients receiving Carfilzomib treatment require regular medical monitoring, including blood tests, kidney function assessments, liver function evaluations, heart health monitoring, and routine clinical examinations to ensure treatment safety and effectiveness.
Due to its targeted mechanism of action and proven clinical benefits, CARFLIEVA 60 MG has become an important treatment option in modern Multiple Myeloma management worldwide.
View Details
Dasatinib Tablet IP 50mg
DASALIEVA 50 MG (Dasatinib Tablet IP 50 mg) is a prescription anticancer medicine containing Dasatinib 50 mg, a targeted therapy used for the treatment of specific types of blood cancers, particularly Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). Dasatinib belongs to a class of medicines known as Tyrosine Kinase Inhibitors (TKIs), which work by blocking abnormal proteins that promote the growth and survival of cancer cells.
Blood cancers such as CML occur when genetic mutations cause abnormal white blood cells to multiply uncontrollably. One of the key abnormalities associated with these cancers is the formation of the BCR-ABL protein, which continuously signals cancer cells to grow and divide. DASALIEVA 50 MG targets and inhibits this protein, helping to slow disease progression and control cancer growth.
Unlike traditional chemotherapy, Dasatinib is a targeted therapy designed to specifically attack cancer-related pathways while minimizing damage to healthy cells. This targeted mechanism has made Dasatinib an important treatment option for patients diagnosed with certain forms of leukemia.
DASALIEVA 50 MG is commonly prescribed for:
Chronic Myeloid Leukemia (CML)
Newly Diagnosed Chronic Phase CML
Resistant or Intolerant CML
Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Advanced Phase CML
Blast Phase Leukemia
Targeted Blood Cancer Treatment
Long-Term Leukemia Management Programs
The medicine is widely used in hematology and oncology practices and may be prescribed as first-line treatment or for patients who have not responded adequately to other therapies.
Manufactured according to stringent pharmaceutical quality standards, DASALIEVA 50 MG is designed to provide consistent quality, effectiveness, and patient safety.
Patients receiving Dasatinib therapy require regular medical monitoring, including complete blood counts, liver function tests, and clinical evaluations to assess treatment response and detect potential side effects.
Due to its proven effectiveness in leukemia management, DASALIEVA 50 MG remains an essential targeted therapy in modern cancer care worldwide.
View Details
Eltrombopag Olamine Tablets 50mg
TROMLIEVA 50 MG (Eltrombopag Olamine Tablets 50 mg) is a prescription medicine containing Eltrombopag Olamine 50 mg, a thrombopoietin receptor agonist used to increase platelet production in patients with certain blood disorders. It is commonly prescribed for individuals with chronic immune thrombocytopenia (ITP), severe aplastic anemia, and thrombocytopenia associated with chronic hepatitis C under the supervision of a qualified healthcare professional.
Platelets are blood cells that play a vital role in blood clotting and preventing excessive bleeding. When platelet levels become too low, patients may experience symptoms such as easy bruising, prolonged bleeding, frequent nosebleeds, bleeding gums, or tiny red spots on the skin known as petechiae. TROMLIEVA 50 MG helps address this problem by stimulating the body’s natural platelet production process.
Eltrombopag works by activating thrombopoietin receptors located in the bone marrow. These receptors are responsible for signaling the production of platelets. By stimulating these receptors, TROMLIEVA 50 MG helps increase platelet counts and reduce the risk of bleeding complications.
Unlike platelet transfusions, which provide a temporary increase in platelet levels, Eltrombopag encourages the body to produce its own platelets, making it a valuable option for long-term management in eligible patients.
TROMLIEVA 50 MG is commonly prescribed for:
Chronic Immune Thrombocytopenia (ITP)
Severe Aplastic Anemia
Low Platelet Counts Due to Chronic Hepatitis C
Bone Marrow Failure Disorders
Platelet Support During Treatment Programs
Long-Term Management of Thrombocytopenia
Hematology Treatment Protocols
Blood Disorder Management Programs
The medicine is often recommended when other treatments have not provided adequate platelet improvement or when long-term platelet support is required.
Manufactured according to stringent pharmaceutical quality standards, TROMLIEVA 50 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Eltrombopag therapy typically require routine blood tests, platelet count monitoring, liver function assessments, and regular medical evaluations to ensure safe and effective treatment.
Due to its proven ability to increase platelet production, TROMLIEVA 50 MG has become an important treatment option in modern hematology care.
View Details
Eltrombopag Olamine Tablets 25mg
TROMLIEVA 25 MG (Eltrombopag Olamine Tablets 25 mg) is a prescription medicine containing Eltrombopag Olamine 25 mg, a thrombopoietin receptor agonist used to increase platelet production in patients suffering from certain blood disorders associated with low platelet counts. It is commonly prescribed for the treatment of Chronic Immune Thrombocytopenia (ITP), Severe Aplastic Anemia, and thrombocytopenia associated with chronic hepatitis C infection.
Platelets are essential blood components that help the body form clots and prevent excessive bleeding. When platelet levels become abnormally low, patients may experience symptoms such as easy bruising, prolonged bleeding, nosebleeds, bleeding gums, fatigue, and the appearance of tiny red or purple spots on the skin. TROMLIEVA 25 MG helps stimulate the body's natural platelet production process, reducing the risk of bleeding complications.
Eltrombopag works by activating thrombopoietin receptors found in the bone marrow. These receptors play a key role in the production of platelets. By stimulating these receptors, TROMLIEVA 25 MG encourages the bone marrow to produce more platelets, helping restore healthier platelet levels in the bloodstream.
Unlike platelet transfusions that provide only temporary support, Eltrombopag promotes sustained platelet production by the body's own cells, making it an effective long-term treatment option for many eligible patients.
TROMLIEVA 25 MG is commonly prescribed for:
Chronic Immune Thrombocytopenia (ITP)
Severe Aplastic Anemia (SAA)
Hepatitis C-Associated Thrombocytopenia
Bone Marrow Failure Disorders
Platelet Production Support Therapy
Long-Term Management of Low Platelet Counts
Hematology Treatment Programs
Blood Disorder Management
The medicine may be prescribed when conventional therapies have failed to provide adequate improvement in platelet counts or when long-term platelet management is required.
Manufactured under stringent pharmaceutical quality standards, TROMLIEVA 25 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Eltrombopag therapy typically require regular blood tests, platelet monitoring, liver function assessments, and routine clinical evaluations to ensure safe and effective treatment.
Due to its proven ability to stimulate platelet production, TROMLIEVA 25 MG has become an important therapeutic option in modern hematology practice.
View Details
